Journals / Journal of critical and intensive care (Online) / 2022 / Cilt: 13 - Sayı: 1

Persistence of Abnormal Inflammatory and Coagulation Laboratory Tests in Critically-ill COVID-19 Survivors: Case Series

Pages
1–7
Publication Date
2022-10-19
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Overall median value (Interquartile range) for the latest abnormal test result dates from the first day of ICU admission and the ratio of patients with abnormal test results after hospital discharge were 11 (7.5-17) days and 7.7% for lymphocyte count, 15 (8-20) days and 20% for LDH, 15 (10.5-40) days and 30% for CRP, 15.5 (10.3-30.3) days and 25% for ferritin, 17 (12-95.5) days and 50% for fibrinogen, and 28 (18-68.5) days and 71.4% for D-dimer.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Aim: In this study, the aim was to evaluate the persistence of abnormalities in laboratory variables regarding inflammation and coagulation during the recovery process of the critically-ill COVID-19 patients.
📊
Key Findings & Data:Materials and methods: Medical records of patients who were treated for COVID-19 in our intensive care unit (ICU) were examined retrospectively.
💡
Conclusion & Impact:Overall median value (Interquartile range) for the latest abnormal test result dates from the first day of ICU admission and the ratio of patients with abnormal test results after hospital discharge were 11 (7.5-17) days and 7.7% for lymphocyte count, 15 (8-20) days and 20% for LDH, 15 (10.5-40) days and 30% for CRP, 15.5 (10.3-30.3) days and 25% for ferritin, 17 (12-95.5) days and 50% for fibrinogen, and 28 (18-68.5) days and 71.4% for D-dimer.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Aim: In this study, the aim was to evaluate the persistence of abnormalities in laboratory variables regarding inflammation and coagulation during the recovery process of the critically-ill COVID-19 patients. Materials and methods: Medical records of patients who were treated for COVID-19 in our intensive care unit (ICU) were examined retrospectively. Baseline characteristics and latest abnormal test result dates for lymphocyte counts, C-reactive protein (CRP), lactate dehydrogenase (LDH), ferritin, fibrinogen and D-dimer levels from the first day of ICU admission were noted. Results: In total, 15 patients were enrolled in the final analysis. Overall median value (Interquartile range) for the latest abnormal test result dates from the first day of ICU admission and the ratio of patients with abnormal test results after hospital discharge were 11 (7.5-17) days and 7.7% for lymphocyte count, 15 (8-20) days and 20% for LDH, 15 (10.5-40) days and 30% for CRP, 15.5 (10.3-30.3) days and 25% for ferritin, 17 (12-95.5) days and 50% for fibrinogen, and 28 (18-68.5) days and 71.4% for D-dimer. Conclusion: In critically-ill COVID-19 survivors, abnormality of laboratory tests regarding inflammation and coagulopathy persists after hospital discharge and even after 90 days after ICU admission which suggests the probability of sustained risk for multi-organ damage and thromboembolic events.

🔖

Cite This Article

ER, B., TOPELİ, A., ERSOY, E. O., ÖCAL, S., HALAÇLI, B., GELDİGİTTİ, İ. T., YILDIRIM, M., TOK, G. (2022). Persistence of Abnormal Inflammatory and Coagulation Laboratory Tests in Critically-ill COVID-19 Survivors: Case Series. Journal of critical and intensive care (Online), Cilt: 13 - Sayı: 1, 1–7. https://ajindex.com/articles/562261

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (13)

  1. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 March 2020. https://www.who.int/dg/speeches/ detail/who-director-general-s-opening-remarks-at-the-mediabriefing-on-covid-19---11-march-2020 2. Singhal T. A Review of Coronavirus Disease-2019(COVID-19). Indian J Pediatr 2020
  2. 281–6. [CrossRef] 3. Halacli B, Kaya A, Topeli A. Critically-ill COVID-19 patient. Turk J Med Sci 2020 21
  3. 50(SI-1):585–91. [CrossRef] 4. Frater JL, Zini G, d’Onofrio G, et al. COVID-19 and the clinical hematology laboratory. Int J Lab Hematol 2020
  4. 42 Suppl 1:11–8. [CrossRef] 5. Lippi G, Plebani M. The critical role of laboratory medicine during coronavirus disease 2019(COVID-19)and other viral outbreaks. Clin Chem Lab Med 2020 25
  5. 1063–9. [CrossRef] 6. Qin C, Zhou L, Hu Z, et al. Dysregulation of Immune Response in Patients With Coronavirus 2019(COVID-19)in Wuhan, China. Clin Infect Dis 2020
  6. 762–8. [CrossRef] 7. Du R-H, Liang L-R, Yang C-Q, et al. Predictors of mortality for patients with COVID-19 pneumonia caused by SARS-CoV-2: a prospective cohort study. Eur Respir J 2020
  7. 2000524. [CrossRef] 8. Henry BM, de Oliveira MHS, Benoit S, et al. Hematologic, biochemical and immune biomarker abnormalities associated with severe illness and mortality in coronavirus disease 2019(COVID-19): a meta-analysis. Clin Chem Lab Med 2020
  8. 1021–8. [CrossRef] 9. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab Med 2020 25
  9. 1116–20. [CrossRef] 10. Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost 2020
  10. 844–7. [CrossRef] 11. Lippi G, Favaloro EJ. D-dimer is Associated with Severity of Coronavirus Disease 2019: A Pooled Analysis. Thromb Haemost 2020
  11. 876–8. [CrossRef] 12. World Health Organization (WHO). COVID-19 clinical management: living guidance, 25 January 2021. World Health Organization. https://apps.who.int/iris/handle/10665/338882 13. Elshazli RM, Toraih EA, Elgaml A, et al. Diagnostic and prognostic value of hematological and immunological markers in COVID-19 infection: A meta-analysis of 6320 patients. PLoS One 2020
  12. e0238160. [CrossRef] 14. Velavan TP, Meyer CG. Mild versus severe COVID-19: Laboratory markers. Int J Infect Dis 2020
  13. 304–7. [CrossRef] 15. Corrêa TD, Cordioli RL, Campos Guerra JC, et al. Coagulation profile of COVID-19 patients admitted to the ICU. An